Shares of Prothena Co. PLC (NASDAQ:PRTA) have earned a consensus rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.
Several research firms have commented on PRTA. BidaskClub lowered Prothena from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 15th. ValuEngine upgraded Prothena from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Prothena from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Wednesday, June 19th. Finally, Barclays reiterated a “sell” rating and set a $9.00 price objective on shares of Prothena in a research note on Friday, May 31st.
Shares of PRTA stock traded down $0.03 on Friday, hitting $8.48. The company had a trading volume of 7,256 shares, compared to its average volume of 217,861. The firm has a market cap of $339.55 million, a P/E ratio of -2.35 and a beta of 2.18. The company has a 50-day moving average price of $8.41 and a 200-day moving average price of $10.18. The company has a quick ratio of 14.95, a current ratio of 14.94 and a debt-to-equity ratio of 0.07. Prothena has a twelve month low of $6.71 and a twelve month high of $14.77.
Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.16. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.22 million. Prothena had a negative return on equity of 27.59% and a negative net margin of 10,435.79%. Equities research analysts expect that Prothena will post -1.97 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can purchased a new position in Prothena in the second quarter valued at $36,000. Meeder Asset Management Inc. purchased a new position in shares of Prothena during the second quarter worth about $37,000. Prudential Financial Inc. purchased a new position in shares of Prothena during the second quarter worth about $109,000. SG Americas Securities LLC purchased a new position in shares of Prothena during the first quarter worth about $114,000. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Prothena by 309.5% during the first quarter. BNP Paribas Arbitrage SA now owns 11,061 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 8,360 shares during the last quarter. Institutional investors and hedge funds own 96.83% of the company’s stock.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Further Reading: Why does a company issue an IPO?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.